CRANBURY, N.J.--(BUSINESS WIRE)--Pharmaceutical Executive, a multimedia platform for industry leaders to exchange experiences and insights about innovative business and marketing ideas, has released its annual Pharma50 list for 2019. Now in its 19th year, the list reveals that companies are now focusing on diversification, big brand expansions and positioning a new wave of products.
“With all the different dynamics at play, the importance of having strong and stable leadership has perhaps never been more critical for biopharma,” said Tom Ehardt, president of MultiMedia Healthcare, LLC. “Pharmaceutical Executive’s Pharma50 list provides an insightful look into the sales performance of these companies and how they are achieving those goals.”
The results show Pfizer in the top spot for the fourth straight year. Through data provided in partnership with life sciences market intelligence firm Evaluate Ltd, Pfizer’s 2018 prescription drug revenue totaled $45.3 billion. Pfizer’s sales of breast cancer drug Ibrance spiked 31.7% last year from 2017 full-year figures.
Coming in second and third are Roche and Novartis, respectively, with Roche inching past Novartis with an increase of 6.8% in prescription drug sales. Roche also spent more than any company on research and development: $9.8 billion.
To view a complete list of the Pharma50, click here.
About Pharmaceutical Executive
Pharmaceutical Executive is a multimedia platform that offers news, opinions, analysis, features and executive profiles. This digital resource serves as a forum for industry leaders to exchange opinions, experiences and insights about innovative business and marketing ideas, strategies and tactics. Pharmaceutical Executive is part of MultiMedia Healthcare, LLC.